MarketBeat
23 Jul 2026, 23:06 UTC · 14w ago
Edwards Lifesciences Q2 Earnings Call Highlights
Impact · against what's priced in
Edwards Lifesciences shows strong operational momentum through raised revenue floors and explosive growth in TMTT. However, the positive top-line news is partially offset by margin pressure and a higher expected tax rate, though overall sentiment remains positive due to strategic scaling.
- EW+0.40
No priced-in read yet
- In context
The company raised the floor of its 2026 sales growth guidance to 10%-11% and saw TMTT sales surge 44.8%, signaling successful scaling of new platforms. This growth is tempered by a shift toward the lower end of gross margin guidance (78%-79%) and a higher expected tax rate due to Pillar Two impacts.
Read from the article alone
